ClinicalTrials.gg
RecruitingNCT06865482Updated Oct 19, 2026

Clinical Course Of Disease In Participants With FA-CM

An observational study in Friedreich Ataxia and Cardiomyopathy, sponsored by Lexeo Therapeutics. Recruiting at 19 sites in 8 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Lexeo Therapeutics · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Oct 19, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
65
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Planned enrollment
11th of 21
65 · median 65
Started
2025
with 3 others
Observational
21 of 71
8 open now
Primary completion
2027-09
later than 6 of 24 live
Registered
61st of 71
by date
Lead sponsor
3 of 71
Lexeo Therapeutics

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 11th largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2025, is one of 21 observational ones, reaches primary completion later than 6 of the 24 other live ones, and was the 61st registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)

Read the detailed description

Study LX2006-02 is a prospective, longitudinal, low-intervention, multicenter, global study aimed at characterizing the nature and rate of cardiac disease progression in participants with genetically confirmed FA.

03

Conditions studied

  • Friedreich Ataxia
  • Cardiomyopathy

Keywords

  • Friedreich Ataxia
  • FA-CM
  • Cardiomyopathy
  • FA
  • Cardiac Disease
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Up to 65 participants with genetically confirmed FA-CM will be enrolled in the study with allocation by age categories and cohorts

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ages ≥6 years at the time of signing the (and assent, if applicable).
  • Diagnosis of FA, based on clinical phenotype and genotype (GAA expansion on both alleles or compound heterozygous), with onset of FA occurring at ≤25 years of age
  • Confirmed left ventricular hypertrophy (LVH)
  • ≥30%

Exclusion criteria

Exclusion Criteria:

  • Presence of other form(s) of CM contributing to heart failure (HF), cardiac anatomic abnormality or congenital cardiac malformation, clinically significant coronary artery, uncorrected, hemodynamically significant primary structural valvular disease not due to CM
  • Currently receiving intermittent or continuous intravenous (IV) inotrope infusion, presence of a ventricular assist device, or history of prior heart transplantation
  • to cMRI, participants \<12 years of age who cannot complete the cMRI without sedation will instead undergo ECHOs and are exempt from this criterion.
  • Prior organ transplantation
  • Initiation of cardiac resynchronization therapy (CRT) within 6 months prior to screening.
  • History of prior gene transfer or cell therapy.
  • Poorly controlled diabetes ( ≥8%)
  • Active hematologic or solid organ
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
65 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Participants ≥16 years of age with FA-CM

    Participants ≥16 years of age with FA-CM

  • Cohort 2: Participants ≥6 to <16 years of age with FA-CM

    Participants ≥6 to \<16 years of age with FA-CM

06

What researchers measure

Primary outcomes

  1. Characterize cardiac disease presentation and progression among participants

    Change from baseline in left ventricular mass index (LVMi)

    Time frame: 52 weeks

Secondary outcomes

  1. Describe progression of maximal wall thickness (MWT) among this population

    Change from baseline

    Time frame: 52 weeks

  2. Describe progression of high sensitivity troponin I among this population

    Change from baseline

    Time frame: 52 weeks

  3. Describe participant perception and clinician assessment of illness in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12)

    Change from baseline

    Time frame: 52 weeks

  4. Describe clinician assessment of illness in modified Friedreich Ataxia Rating Scale (mFARS)

    Change from baseline

    Time frame: 52 weeks

  5. Describe participant perception of illness in Patient Global Impression of Severity (PGI-S)

    Change from baseline

    Time frame: 52 weeks

  6. Describe participant perception of illness in Patient Global Impression of Change (PGI-C)

    Change from baseline

    Time frame: 52 weeks

  7. Describe patterns of concomitant medication use among this population

    Change from baseline in concomitant medication use, assessed using medication logs, electronic health records and patient self-report.

    Time frame: 52 weeks

  8. Describe changes to medication use among this population

    Change from baseline in medication use, evaluated using prescription records, patient-reported medication, or clinician-reported changes.

    Time frame: 52 weeks

  9. Evaluate cardiovascular (CV) events

    Number of CV events defined as death due to any cause plus adjudicated events of hospitalization for heart failure, non-fatal stroke, non-fatal myocardial infarction, non-fatal life-threatening arrhythmia, heart transplant, implantation of left ventricular assisted device (LVAD)

    Time frame: 52 weeks

  10. Cumulative measure of CV and non-CV related health care utilization (HRU)

    Health care utilization will be assessed through a combination of: * Data captured via Electronic Data Capture (EDC) system (e.g., hospitalizations, emergency room visits, procedures), * Patient-reported information collected by the physician during scheduled study visits.

    Time frame: 52 Weeks

07

Study locations

18 of 19 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Mar 7, 2025
StartActual
Sep 30, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Oregon Health & Science University is now Withdrawn
Oct 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Oregon Health & Science University · Portland, United StatesContact removed v•••@ohsu.edu
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Oregon Health & Science University is now Withdrawn
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Oregon Health & Science University · Portland, United StatesContact removed v•••@ohsu.edu

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06865482
Lead sponsor
Lexeo Therapeutics
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Sep 30, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Lexeo Clinical Trials
Contact
clinicaltrials@lexeotx.com
212-547-9879
Lexeo Clinical Trials
study director · Lexeo Therapeutics

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion